Mechanism of action of avatrombopag and eltrombopag

Avatrombopag and eltrombopag are both thrombopoietin receptor (TPO-R) agonists, but they have slightly different chemical structures and mechanisms of action. Avatrombopag is a small molecule organic compound that stimulates platelet production in the bone marrow and increases the number of platelets by combining with TPO-R. It is used to treat idiopathic thrombocytopenic purpura (ITP). Eltrombopag is a polypeptide drug that stimulates platelet production in the bone marrow by binding to TPO-R and increases the number of platelets. It is also used to treat ITP. Although both increase platelet production by activating TPO-R, their specific mechanisms of action and efficacy may differ due to different chemical structures and drug properties. Therefore, during use, doctors will select appropriate drugs based on the patient's condition and condition, and make adjustments and monitoring as needed.